Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02070380 · ClinicalTrials.gov registry record · Phase 4
Crossover Comparison of MultiHance and Dotarem
A Phase 4 study, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- Phase 4
- Development phase
- 179
- Enrollment target
NCT02070380 is a Phase 4 study that has completed, run by Bracco Diagnostics. The registered enrollment target is 179 participants.
The verdict
NCT02070380, a Phase 4 study, has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 179 participants
- Enrollment target
Study Summary
This study aims at a comparison between MultiHance at a dose of 0.1 mmol/kg and 0.05 mmol/kg and Dotarem at a dose of 0.1 mmol/kg in brain tumor patients to show superiority of MultiHance.
Interventions
- DRUG Dotarem
- DRUG MultiHance 0.1 mmol/kg
- DRUG MultiHance 0.05 mmol/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02070380
The ClinicalTrials.gov registry entry for NCT02070380 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 179 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dotarem is the first listed.
NCT02070380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02070380 about?
NCT02070380 is a clinical study titled "Crossover Comparison of MultiHance and Dotarem". This study aims at a comparison between MultiHance at a dose of 0.1 mmol/kg and 0.05 mmol/kg and Dotarem at a dose of 0.1 mmol/kg in brain tumor patients to show superiority of MultiHance.
What is the current status of trial NCT02070380?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 179 participants. The study started on 2014-02. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02070380?
The interventions under investigation include: Dotarem (DRUG), MultiHance 0.1 mmol/kg (DRUG), MultiHance 0.05 mmol/kg (DRUG).
Who is sponsoring clinical trial NCT02070380?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.